title: Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies.
abstract: BACKGROUND
  Trans-resveratrol rather than its biotransformed monosulfate metabolite exerts anti-medulloblastoma effects by suppressing STAT3 activation. Nevertheless, its effects on human glioblastoma cells are variable due to certain unknown reason(s).
  
  
  RESULTS
  Citing resveratrol-sensitive UW228-3 medulloblastoma cell line and primarily cultured rat brain cells/PBCs as controls, the effect of resveratrol on LN-18 human glioblastoma cells and its relevance with metabolic pattern(s), brain-associated sulfotransferase/SULT expression and the statuses of STAT3 signaling and protein inhibitor of activated STAT3 (PIAS3) were elucidated by multiple experimental approaches. Meanwhile, the expression patterns of three SULTs (SULT1A1, 1C2 and 4A1) in human glioblastoma tumors were profiled immunohistochemically. The results revealed that 100 µM resveratrol-treated LN-18 generated the same metabolites as UW228-3 cells, while additional metabolite in molecular weight of 403.0992 in negative ion mode was found in PBCs. Neither growth arrest nor apoptosis was found in resveratrol-treated LN-18 and PBC cells. Upon resveratrol treatment, the levels of SULT1A1, 1C2 and 4A1 expression in LN-18 cells were more up-regulated than that expressed in UW228-3 cells and close to the levels in PBCs. Immunohistochemical staining showed that 42.0%, 27.1% and 19.6% of 149 glioblastoma cases produced similar SULT1A1, 1C2 and 4A1 levels as that of tumor-surrounding tissues. Unlike the situation in UW228-3 cells, STAT3 signaling remained activated and its protein inhibitor PIAS3 was restricted in the cytosol of resveratrol-treated LN-18 cells. No nuclear translocation of STAT3 and PIAS3 was observed in resveratrol-treated PBCs. Treatment with STAT3 chemical inhibitor, AG490, committed majority of LN-18 and UW228-3 cells but not PBCs to apoptosis within 48 hours.
  
  
  CONCLUSIONS
  LN-18 glioblastoma cells are insensitive to resveratrol due to the more inducible brain-associated SULT expression, insufficiency of resveratrol to suppress activated STAT3 signaling and the lack of PIAS3 nuclear translocation. The findings from PBCs suggest that an effective anticancer dose of resveratrol exerts little side effect on normal brain cells.
authors.affiliation: Liaoning Laboratory of Cancer Genetics & Epigenetics, Department of Cell Biology, Dalian Medical University, Dalian, China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Shu
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.forename: Xiao-Xin
authors.initials: XX
authors.lastname: Sun
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Sun
authors.forename: Mo-Li
authors.initials: ML
authors.lastname: Wu
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Chen
authors.forename: Chong
authors.initials: C
authors.lastname: Li
authors.forename: Qing-You
authors.initials: QY
authors.lastname: Kong
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015239:Arylsulfotransferase / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D018832:Molecular Chaperones / Q000235:genetics / Q000378:metabolism; D050828:Protein Inhibitors of Activated STAT / Q000235:genetics / Q000378:metabolism; D051381:Rats; D000077185:Resveratrol; D050796:STAT3 Transcription Factor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013267:Stilbenes / Q000494:pharmacology*; D015238:Sulfotransferases / Q000235:genetics / Q000378:metabolism; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D018832:Molecular Chaperones; C484745:PIAS3 protein, human; D050828:Protein Inhibitors of Activated STAT; D050796:STAT3 Transcription Factor; D013267:Stilbenes; D020032:Tyrphostins; C095512:alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; C479953:SULT4A1 protein, human; C513319:SULT1C2 protein, human; D015238:Sulfotransferases; D015239:Arylsulfotransferase; C117544:SULT1A1 protein, human; D000077185:Resveratrol
references.citation: Mol Cancer Res. 2008 May;6(5):675-84
references.pmid: 18505913
references.citation: Neoplasia. 2008 Jul;10(7):736-44
references.pmid: 18592012
references.citation: Mol Cancer Ther. 2006 Mar;5(3):621-9
references.pmid: 16546976
references.citation: Drug Metab Dispos. 2007 May;35(5):699-703
references.pmid: 17287390
references.citation: Science. 2008 Sep 26;321(5897):1807-12
references.pmid: 18772396
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):953-7
references.pmid: 14578128
references.citation: Neoplasia. 2006 Oct;8(10):817-25
references.pmid: 17032498
references.citation: Curr Mol Med. 2009 Jun;9(5):580-90
references.pmid: 19601808
references.citation: J Neurooncol. 2010 Dec;100(3):339-43
references.pmid: 20455003
references.citation: Clin Cancer Res. 2008 Aug 1;14(15):4694-704
references.pmid: 18676737
references.citation: Biochem Pharmacol. 2010 May 15;79(10):1516-25
references.pmid: 20105429
references.citation: Cancer Res. 1993 Nov 15;53(22):5345-9
references.pmid: 7693337
references.citation: Anticancer Drugs. 2010 Feb;21(2):140-50
references.pmid: 20010425
references.citation: Mol Nutr Food Res. 2005 May;49(5):472-81
references.pmid: 15779070
references.citation: Clin Chem. 2007 Feb;53(2):292-9
references.pmid: 17170057
references.citation: CA Cancer J Clin. 2010 May-Jun;60(3):166-93
references.pmid: 20445000
references.citation: Stem Cells. 2009 Oct;27(10):2383-92
references.pmid: 19658181
references.citation: J Cell Physiol. 2012 Mar;227(3):976-93
references.pmid: 21503893
references.citation: PLoS One. 2010 Dec 28;5(12):e15627
references.pmid: 21209944
references.citation: Arch Biochem Biophys. 2009 Jun 15;486(2):95-102
references.pmid: 19514131
references.citation: Mol Nutr Food Res. 2010 Jan;54(1):7-16
references.pmid: 20013887
references.citation: J Histochem Cytochem. 2003 Dec;51(12):1655-64
references.pmid: 14623933
references.citation: PLoS One. 2011;6(6):e20849
references.pmid: 21695150
references.citation: Blood. 2007 Mar 15;109(6):2293-302
references.pmid: 17164350
references.citation: Mol Cancer Ther. 2008 Nov;7(11):3519-26
references.pmid: 19001435
references.citation: PLoS One. 2010 Sep 23;5(9):e12935
references.pmid: 20886076
references.citation: EMBO J. 2000 Nov 1;19(21):5845-55
references.pmid: 11060035
references.citation: Mol Nutr Food Res. 2008 Jun;52(6):683-91
references.pmid: 18398872
references.citation: Oncol Res. 1995;7(10-11):493-503
references.pmid: 8866661
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):6042-54
references.pmid: 18829483
references.citation: Drug Metab Dispos. 2009 Apr;37(4):706-9
references.pmid: 19171676
references.citation: PLoS Biol. 2007 May;5(5):e97
references.pmid: 17425406
references.citation: Neurosci Lett. 2003 Nov 13;351(2):83-6
references.pmid: 14583387
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 27;829(1-2):97-106
references.pmid: 16243591
references.citation: Cancer Lett. 2008 Mar 18;261(2):172-82
references.pmid: 18082939